Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA).

Full DD Report for DRNA

You must become a subscriber to view this report.


Recent News from (NASDAQ: DRNA)

Dicerna to Participate in Upcoming Investor Conferences
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in three investor conferences in November. ...
Source: Business Wire
Date: November, 06 2018 07:30
Dicerna Pharmaceuticals, Inc. (DRNA) CEO Douglas Fambrough on Q3 2018 Results - Earnings Call Transcript
Dicerna Pharmaceuticals, Inc. (DRNA) Q3 2018 Results Earnings Conference Call November 05, 2018, 04:30 PM ET Executives Paula Schwartz - Investor Relations Douglas Fambrough - President and CEO Jack Green - CFO Ralf Rosskamp - Chief Medical Officer Analysts Stephen Willey...
Source: SeekingAlpha
Date: November, 05 2018 22:54
Dicerna Pharmaceuticals misses by $0.09, misses on revenue
Dicerna Pharmaceuticals (NASDAQ: DRNA ): Q3 GAAP EPS of -$0.35 misses by $0.09 . More news on: Dicerna Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 05 2018 16:13
Dicerna Reports Third Quarter 2018 Financial and Operating Results and Provides Corporate Update
Demonstrated Clinical POC for DCR-PHXC in Primary Hyperoxaluria and On Track to Initiate Registration Trial in Q1 2019 Entered into Strategic Collaborations with Lilly and Alexion to Discover and Develop RNAi Therapies Using Dicerna’s GalXC™ Technology Platform Close...
Source: Business Wire
Date: November, 05 2018 16:05
Dicerna Pharmaceuticals Keeps The Deals Rolling In On The Promise Of Its Groundbreaking GalXC RNAi Technology
Recently, Dicerna Pharmaceuticals ( DRNA ) announced a partnership with Eli Lilly ( LLY ) which amounts to an upfront payment and an equity stake . This is just one of the most recent validations of Dicerna's GalXC technology. Just this past week, Dicerna garnered another deal with Ale...
Source: SeekingAlpha
Date: October, 30 2018 09:54
Dicerna to Report Third Quarter 2018 Financial Results and Host Conference Call on November 5, 2018
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2018 financial results after market close on Monday, November 5, 2018. Management will...
Source: Business Wire
Date: October, 30 2018 07:30
Stronger than expected earnings lead stocks higher premarket
Red Hat (NYSE: RHT ) +49%  on being acquired by IBM. More news on: Red Hat, Inc., Diana Containerships Inc., China Recycling Energy Corporation, Stocks on the move, , Top stock market news, Read more ...
Source: SeekingAlpha
Date: October, 29 2018 09:27
Dicerna up 23% premarket on RNAi therapeutics deal with Eli Lilly
Eli Lilly (NYSE: LLY ) and Dicerna Pharmaceuticals (NASDAQ: DRNA ) ink a global licensing and research collaboration agreement aimed at discovering, developing and commercializing new RNAi therapeutics in cardio-metabolic disease, neurodegeneration and pain. The partnership will leverage D...
Source: SeekingAlpha
Date: October, 29 2018 07:09
Lilly and Dicerna Announce RNAi Licensing and Research Collaboration
INDIANAPOLIS and CAMBRIDGE, Mass. , Oct. 29, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Dicerna Pharmaceuticals (NASDAQ: DRNA) today announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medic...
Source: PR Newswire
Date: October, 29 2018 06:00
Dicerna Announces Late-Breaking Data Supporting Use of DCR-PHXC in Adults with Primary Hyperoxaluria Types 1 and 2 (PH1 and PH2)
Single-dose Data from Ongoing PHYOX Phase 1 Trial, Presented at ASN Kidney Week, Show Normalization or Near-normalization of Urinary Oxalate Levels in a Majority of Participants Reductions in Urinary Oxalate, Combined with Favorable Safety/Tolerability Profile, Lay Groundwork for Plann...
Source: Business Wire
Date: October, 25 2018 13:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1313.4512.3513.6512.33248,064
2018-12-1213.0413.5213.7212.9663201,018
2018-12-1112.8712.8713.1412.51214,474
2018-12-1012.9012.7613.0712.52242,170
2018-12-0713.8912.7514.7412.74251,116

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1318,63360,91730.5875Cover
2018-12-1213,49945,99129.3514Cover
2018-12-1110,56934,48330.6499Cover
2018-12-1010,17739,24025.9353Cover
2018-12-0717,23330,69156.1500Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DRNA.


About Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA)

Logo for Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: DRNA)

      Simplified registration form
      Filing Type: S-3Filing Source: edgar
      Filing Date: May, 17 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 14 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 14 2018
      Prospectus filed under Rule 424(b)(3)
      Filing Type: 424B3Filing Source: edgar
      Filing Date: May, 11 2018
      Pre-effective amendment to an S-3 filing
      Filing Type: S-3/AFiling Source: edgar
      Filing Date: May, 04 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 26 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 26 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 26 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 23 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 06 2018

       

       


      Daily Technical Chart for (NASDAQ: DRNA)

      Daily Technical Chart for (NASDAQ: DRNA)


      Stay tuned for daily updates and more on (NASDAQ: DRNA)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: DRNA)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DRNA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of DRNA and does not buy, sell, or trade any shares of DRNA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/